Birgit Zech
Directeur Général chez Anavo Therapeutics BV
Provenance du réseau au premier degré de Birgit Zech
Entité | Type d'entité | Industrie | |
---|---|---|---|
Gotham Therapeutics Corp.
Gotham Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Gotham Therapeutics Corp. develops and manufactures pharmaceutical medicines. The firm develops new treatment options for patients suffering from cancers, auto-immune and neurodegenerative diseases. The company was founded by Samie Jaffrey in 2017 and is headquartered in New York, NY.
3
| Subsidiary | Pharmaceuticals: Major | 3 |
Anavo Therapeutics BV
Anavo Therapeutics BV BiotechnologyHealth Technology Anavo Therapeutics BV is a Dutch company that specializes in developing first-in-class therapeutic programs for several indications in oncology. The company is based in Leiden, Netherlands. The company has attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. Anavo is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. Anavo is backed by blue-chip investors m ventures, inkef capital, taiho ventures, mrl ventures fund, and bioqube ventures. The company was founded by Claus Schalper, Birgit Zech, Gerhard Müller. Birgit Zech has been the CEO since incorporation.
3
| Holding Company | Biotechnology | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Birgit Zech via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
Agouron Pharmaceuticals LLC
Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
ALLERGAN, INC. | Pharmaceuticals: Major | Director/Board Member | |
3I GROUP PLC | Investment Managers | Corporate Officer/Principal | |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
4SC AG | Biotechnology | Director/Board Member | |
WIRECARD AG | Regional Banks | Comptroller/Controller/Auditor | |
MOLMED S.P.A. | Pharmaceuticals: Major | Chairman | |
KALA BIO, INC. | Pharmaceuticals: Major | President | |
WHATMAN | Industrial Machinery | Corporate Officer/Principal | |
MEDIGENE AG | Biotechnology | Director/Board Member | |
Arthur Andersen LLP
Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
University of Bamberg | College/University | Masters Business Admin | |
Numab Therapeutics AG
Numab Therapeutics AG Miscellaneous Commercial ServicesCommercial Services Numab Therapeutics AG is a biopharmaceutical company, which engages in the development of cancer immunotherapy. Its focuses on creating multi-specific antibodies that enable the pursuit of novel therapeutic strategies. The company was founded by Oliver Middendorp, David Urech, and Peter Lichtlen in 2011 and is headquartered in Wadenswil, Switzerland. | Miscellaneous Commercial Services | Director/Board Member | |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member | |
Università degli Studi di Modena e Reggio Emilia | College/University | Doctorate Degree | |
The European Association for Bioindustries | Chairman | ||
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Chairman | |
EryDel SpA
EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Chairman | |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands. | Pharmaceuticals: Major | Chairman | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Chairman | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor | |
DYNE THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman | |
International Rare Diseases Research Consortium | Corporate Officer/Principal | ||
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of San Diego | College/University | Masters Business Admin | |
University of California, Santa Barbara | College/University | Graduate Degree | |
University of California, Santa Cruz | College/University | Undergraduate Degree | |
Impact Biomedicines, Inc.
Impact Biomedicines, Inc. Medical SpecialtiesHealth Technology Impact Biomedicines, Inc. engages in the development of cancer treatments. It engages in the development of fedratinib, a potent and selective oral molecule JAK2 kinase inhibitor for the treatment of myelofibrosis and polycythemia vera. The company was founded by John Hood, Catriona Jamieson and Raghu Saripalli in 2016 and is headquartered in San Diego, CA. | Medical Specialties | President | |
EQUILLIUM, INC. | Biotechnology | Director/Board Member | |
High-Tech Gründerfonds Management GmbH
High-Tech Gründerfonds Management GmbH Investment ManagersFinance High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany. | Investment Managers | Private Equity Investor | |
PIERIS PHARMACEUTICALS, INC. | Biotechnology | Founder | |
Isarna Therapeutics GmbH
Isarna Therapeutics GmbH BiotechnologyHealth Technology Isarna Therapeutics GmbH engages in developing selective TGF-ß inhibitors. It works on a pipeline of novel oligonucleotides and combination modalities to transcend clinical response and improve patient outcome. The company focuses on biopharmaceutical research, pipeline development, and partnering and licensing programs. Isarna Therapeutics was founded by Karl-Hermann Schlingensiepen and Reimar Schlingensiepen in 1998 and is headquartered in Munich, Germany. | Biotechnology | Chief Executive Officer | |
Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Undergraduate Degree | |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member | |
Forbion Capital Partners Germany GmbH | Investment Managers | Corporate Officer/Principal | |
Curetis GmbH
Curetis GmbH Medical SpecialtiesHealth Technology Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany. | Medical Specialties | Director/Board Member | |
EPIGENOMICS AG | Medical Specialties | Director/Board Member | |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Pharmaceuticals: Major | Director/Board Member | |
Johann Wolfgang Goethe-Universität Frankfurt am Main | College/University | Doctorate Degree | |
Allecra Therapeutics GmbH
Allecra Therapeutics GmbH Pharmaceuticals: MajorHealth Technology Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany. | Pharmaceuticals: Major | Chairman |
Statistiques
Internationale
Allemagne | 20 |
Etats-Unis | 14 |
Royaume-Uni | 5 |
Italie | 4 |
Pays-Bas | 3 |
Sectorielle
Health Technology | 28 |
Consumer Services | 9 |
Finance | 7 |
Commercial Services | 5 |
Producer Manufacturing | 2 |
Opérationnelle
Director/Board Member | 23 |
Corporate Officer/Principal | 12 |
Chairman | 11 |
Founder | 6 |
Chief Tech/Sci/R&D Officer | 4 |
Relations les plus connectées
Insiders | |
---|---|
Holger N. Reithinger | 25 |
Carlo Incerti | 14 |
Charles McDermott | 11 |
Claus Schalper | 8 |
Gerhard Müller | 2 |
- Bourse
- Insiders
- Birgit Zech
- Connexions Sociétés